T-47: Assessment of the Quality of Pharmacoeconomic Reports in Taiwan
Poster Presenter
Shu-Mei Hsu
HTA Researcher
TFDA/Center for Drug Evaluation Taiwan
Objectives
The study would like to synthesis the economic model and quality outcome of local pharmacoeconomic (PE) reports for reimbursement of NHIA (National Health Insurance Administration) in Taiwan. The purpose of the study is to realize the potential problem and further guideline revision.
Method
The PE reports were recruited from the application dossiers for reimbursement from 2014 to 2018. Assessment criteria of PE were followed by HTA guideline which has four parts in Taiwan. The final score was consensus from the economic team of HTA and use excels for all analyses.
Results
Primary outcomes would like to illustrate the drug category and PE quality level of the application from the pharmaceutical factory among four parts. Further concern is comparing the quality of first stage PE reports with second stage in order to find out the possible improvement for the PE reports and further guideline suggestion.
Conclusion
The reports collection and data analysis are in progress and final outcomes will be explicitly present in the poster session.
